Introduction
Materials and methods
Patients
Treatment
Outcomes and statistical analyses
Results
Patient characteristics
2D-IGBTa (2007–2016) | 3D-IGBTb (2017–2021) | P value | |
---|---|---|---|
Number of cases | 71 | 61 | |
Follow up period (months) | |||
Median (range) | 72.7 (4.6–183.9) | 30.0 (4.2–70.5) | < 0.0001 |
Age (years) | 65.0 (40–93) | 60.0 (28–87) | 0.0125 |
Stage | |||
Ib/II/III/IVa | 7/28/29/7 | 6/25/21/9 | 0.7998 |
Histology | |||
Squamous ca.c/Adeno.ca.d/Other | 59/10/2 | 59/6/0 | 0.4765 |
Tumor diametere (cm) | 5.0 (1–10) | 5.7 (1–8.6) | 0.1468 |
Pelvic lymph node involvementf | |||
Yes/No | 35/36 | 41/20 | 0.0518 |
Para-aortic lymph node involvement | |||
Yes/No | 11/60 | 14/47 | 0.3732 |
Pretreatment hemoglobin level(g/dL) | 11.1 (7.3–14.8) | 12.0 (6.4–15.0) | 0.1098 |
Overall treatment time (days) | 48 (36–85) | 48 (38–63) | 0.3409 |
Point A dose (Gyg) | 56.1 (40–74) | 64.0 (52–76.8) | < 0.0001 |
HR-CTVh D90 (Gyg) | 70.9 (53.7–93.5) | ||
Bladder D2cc (Gyg) | 77.6 (64.1–105.2) | ||
Rectum D2cc (Gyg) | 58.5 (39.6–58.5) | ||
Sigmoid colon D2cc (Gyg) | 58.2 (35.7–73.8) | ||
Chemotherapy (CTx) | |||
Yes/No | 46/25 | 52/9 | 0.0093 |
Times of CTx | |||
Less than five times/Five times or more | 21/25 | 10/42 | 0.0004 |
Adjuvant CTx | |||
Yes/No | 40/31 | 32/29 | 0.7268 |
Local recurrence (cases) | 10 | 3 | |
Regional recurrencei (cases) | 8 | 4 | |
Distant metastasisj (cases) | 28 | 10 | |
All recurrence (cases) | 32 | 11 |
Tumor response
Late toxicity
Adverse Events ≥ G3 | 2D-IGBT (n = 71) | 3D-IGBT (n = 61) |
---|---|---|
a. Urinary tract | ||
Bleeding | 2 | 0 |
Stenosis | 0 | 1 |
Fistula | 2 | 2 |
Total | 4 | 3 |
b. Gastrointestinal tract | ||
Bleeding | 4 | 2 |
Ileus | 3 | 0 |
Stenosis | 2 | 0 |
Fistula | 4 | 4 |
Total | 13 | 6 |
Recurrence in the 3D-IGBT group | Bladder perforation (No) | Bladder perforation (Yes) | Total |
---|---|---|---|
a. Urinary tract | |||
With bevacizumab | 4 | 1 | 5 |
Without bevacizumab | 5 | 1 | 6 |
Total | 9 | 2 | 11 |
Recurrence in the 3D-IGBT group | Intestinal perforation (No) | Intestinal perforation (Yes) | Total |
---|---|---|---|
b. Gastrointestinal tract | |||
With bevacizumab | 2 | 3 | 5 |
Without bevacizumab | 5 | 1 | 6 |
Total | 7 | 4 | 11 |